A method for impurity purification based on coxib
The alkaline water washing method simplifies the removal process of etoricoxib impurity compound B, solving the problems of cumbersome processes, long cycles, and high costs in existing technologies. It achieves efficient and low-cost etoricoxib purification, ensuring the safety and purity of the drug.
Patent Information
- Application Number
- CN202610442762.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-07
- Publication Date
- 2026-05-26
AI Technical Summary
In the existing etoricoxib synthesis process, the removal methods for compound B (2-chloro-1,3-bis(dimethylamino)trimethylenehexafluorophosphate) are cumbersome, time-consuming, have low yields, and are costly, making it difficult to meet the purity requirements of the drug.
The tetrahydrofuran reaction solution of etoricoxib was washed 1-3 times with alkaline water. Taking advantage of the good solubility of compound B in alkaline water, while etoricoxib is almost insoluble in alkaline water, the purified etoricoxib product was obtained by crystallization after cooling.
The process of removing impurity compound B is simplified, the process cycle is shortened, the cost is reduced, the purity of the drug is improved, and the safety and economy of the drug are ensured.
Smart Images

Figure CN122079875A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical and chemical engineering, and in particular, it relates to a method for purifying impurities based on coxib. Background Technology
[0002] Etoricoxib is a highly selective COX-2 inhibitor that exerts its antipyretic, analgesic, and anti-inflammatory effects by inhibiting COX and reducing the production of prostaglandins (PGs) and thromboxanes. It can be used for rheumatoid arthritis, chronic low back pain in osteoarthritis (OA), and postoperative toothache, providing pain relief and anti-inflammatory effects without the gastrointestinal side effects caused by non-selective COX-1 inhibitors. Etoricoxib was first launched in Mexico, the UK, and Brazil in 2002, and subsequently in countries and regions including the EU, Asia-Pacific, Australia, and Latin America. By the end of 2013, it had been approved for marketing in 97 countries worldwide and is widely used to treat various diseases such as osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea, and postoperative pain.
[0003] Existing technologies rely on the following methods for the synthesis of coxib:
[0004] Route 1: CN1306425A (Application No. 99807550.7)
[0005] This route uses 1-(6-methyl-3-pyridine)-2-[4-(methmercapto)phenyl]-ethyl ketone (compound 22d) as the starting material, which is oxidized under hydrogen peroxide to obtain intermediate 22. This intermediate is then cyclized with 2-chloro-1,3-bis(dimethylamino)trimethylene hexafluorophosphate (compound 24) to obtain target compound 6, which is etoricoxib. The process is as follows:
[0006]
[0007] Route 2: CN1306425A (Application No. 99807550.7)
[0008] Compound 22 was prepared by reacting compounds 22a and 22b with Grignard reactions twice and then with hydrogen peroxide oxidation; compound 24 was prepared by reacting chloroacetyl chloride (compound 24a) with phosphorus oxychloride and sodium hexafluorophosphate; finally, compounds 22 and 24 were cyclized to obtain the target compound 6, as follows:
[0009] Route 3: CN104151232A (Application No. 201410297931.2)
[0010] Starting with compound 20, it was converted to an acyl chloride via thionyl chloride and further esterified (compound 25). Compounds 25 and 22a were then reacted with a Grignard reagent to form compound 2. Finally, compounds 22 and 24 were cyclized to obtain the target compound 6. The process is as follows:
[0011]
[0012] Route 4: CN104693113A (Application No. 201510098138.4)
[0013] Starting with compound 22d-1, compound 22 was obtained through the following processes: methylthiolation with sodium methanethiol, reduction of the aldehyde group with sodium borohydride, hydrogen chlorination of the benzylic hydroxyl group with hydrogen chloride, cyanation with sodium cyanide, condensation, decyanation, and sulfur oxidation with hydrogen peroxide. Finally, compound 22 and compound 24 were cyclized to obtain the target compound 6. The process is as follows:
[0014]
[0015] The synthetic processes used in the aforementioned patents all share a common step: Compound A (1-(6-methyl-3-pyridine)-2-[4-(methmercapto)phenyl]-ethyl ketone) undergoes an electrophilic addition reaction with Compound B (2-chloro-1,3-bis(dimethylamino)trimethylenehexafluorophosphate) under potassium tert-butoxide conditions. The reaction is quenched by adding glacial acetic acid, and finally, the reaction is cyclized in ammonia water by a Schiff base active intermediate to generate etoricoxib (as shown in the chemical formula below). In this synthetic method, Compound B is in excess, and Compound B has a warning structure indicating genotoxic impurities. Currently, most post-processing involves salt formation followed by dissociation for purification, or multiple purification processes. This is not only cumbersome but also time-consuming, has low yields, and wastes energy and manpower.
[0016] . Summary of the Invention
[0017] To overcome the shortcomings of the existing methods, this invention provides a method for purifying etoricoxib impurities. This method is simple to operate and low in cost. The content of 2-chloro-1,3-bis(dimethylamino)trimethylenehexafluorophosphate in the crude etoricoxib obtained by this method can easily be reduced to below 12.5 ppm.
[0018] The technical solution adopted by this invention to solve its technical problem is:
[0019] A method for purifying impurities based on coxib includes the following steps:
[0020] Step (1) Prepare the tetrahydrofuran reaction solution of etoricoxib. Specifically, let compound A and compound B undergo an electrophilic addition reaction under potassium tert-butoxide conditions according to the required reaction ratio. That is, obtain the amount of compound A and compound B that can react with each other to complete the electrophilic addition reaction according to the required reaction ratio. Then let them react, and then add them to glacial acetic acid to complete the quenching reaction. Finally, heat in ammonia water to generate etoricoxib by cyclization of Schiff base active intermediate, thereby obtaining the tetrahydrofuran reaction solution of etoricoxib. Among them, compound A is 1-(6-methyl-3-pyridine)-2-[4-(methmercapto)phenyl]-ethyl ketone, and compound B is 2-chloro-1,3-bis(dimethylamino)trimethylene hexafluorophosphate.
[0021] Step (2) Wash the tetrahydrofuran reaction solution of etoricoxib obtained in step (1) with an inorganic alkali solution 1-3 times. The inorganic alkali content in the inorganic alkali solution is 1wt%-10wt%. Each time, add the inorganic alkali solution to the tetrahydrofuran reaction solution of etoricoxib at a ratio of compound A mass to inorganic alkali solution volume of 10 g : (10-50) mL (i.e. 1: (1-5) g / mL). After stirring, let it stand to separate into layers. After separating the aqueous layer, one alkali wash is completed. After the last alkali wash, cool down to crystallize and finally obtain the purified etoricoxib product.
[0022] The reason for choosing this method of removing impurity compound B is that, during the optimization of the recrystallization purification method, the inventors discovered that both compound B and etoricoxib are soluble in most solvents. To purify compound B to a acceptable level, multiple recrystallization processes were required. Further investigation during mixed solvent recrystallization revealed that compound B has good solubility in alkaline water, while etoricoxib is almost insoluble in alkaline water. Therefore, washing the etoricoxib reaction solution with alkaline water was tested and found to have a strong impurity removal effect. A subsequent recrystallization purification process yielded a qualified product with stable results. The specific mechanism of this effect is still under investigation, but those skilled in the art can reliably reproduce this effect under the conditions described in this specification.
[0023] The process of obtaining the tetrahydrofuran reaction solution of etoricoxib in step (1) above is a commonly used technique in the prior art.
[0024] The cooling and crystallization process after the last alkaline wash in step (2) above is also a commonly used technique in the prior art.
[0025] Preferably, in the purification method of the present invention described above, in step (2), during alkaline washing, an inorganic alkaline solution is added to the tetrahydrofuran reaction solution of etoricoxib at a ratio of 10 g: 20 mL for the mass of compound A to the volume of the inorganic alkaline solution.
[0026] Preferably, in the purification method of the present invention described above, the inorganic base in the inorganic base solution is sodium hydroxide, potassium hydroxide, sodium carbonate, etc., and more preferably sodium hydroxide.
[0027] Preferably, in the purification method of the present invention described above, the inorganic alkali content in the inorganic alkali solution is 1wt%-10wt%, more preferably 5wt%.
[0028] Preferably, in the purification method of the present invention described above, the number of alkaline washes is 1-3 times, more preferably 2 times.
[0029] The beneficial effects of this invention are:
[0030] This invention discloses a method for purifying etoricoxib impurities. The process is simple and ingenious, utilizing the difference that compound B (2-chloro-1,3-bis(dimethylamino)trimethylenehexafluorophosphate) has good solubility in alkaline water, while etoricoxib is almost insoluble in alkaline water. A method for removing impurity compound B from etoricoxib by washing with alkaline water has been developed. This method is simple, has a short cycle time, and is low in cost, significantly reducing the preparation cost of qualified etoricoxib formulation raw materials. Ultimately, it allows patients to obtain low-cost and safe drugs, avoiding the problems of previous methods that generally required recrystallization to remove impurity compound B, which were not only cumbersome but also had long cycles, low yields, and wasted energy and manpower. This method has significant social value, strong practicality, and is worthy of promotion. Attached Figure Description
[0031] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0032] Figure 1 A comparison of the solubility of compound B in water, 5 wt% sodium hydroxide solution, and etoricoxib in 5 wt% sodium hydroxide solution;
[0033] Figure 2 The image shows the test spectrum of the etoricoxib sample obtained in Example 1 of this invention;
[0034] Figure 3 The test spectrum of the etoricoxib sample obtained in Example 2 of the present invention.
[0035] Figure 4 The test spectrum of the etoricoxib sample obtained in Example 3 of the present invention;
[0036] Figure 5 The test spectrum of the etoricoxib sample obtained in Example 4 of the present invention;
[0037] Figure 6 The test spectrum of the etoricoxib sample obtained in Example 5 of the present invention;
[0038] Figure 7The test spectrum of the etoricoxib sample obtained in Example 6 of the present invention;
[0039] Figure 8 The image shows the test spectrum of the etoricoxib sample obtained in Example 7 of this invention. Detailed Implementation
[0040] All features disclosed in this specification, or all steps in all disclosed methods or processes, may be combined in any way, except for mutually exclusive features and / or steps.
[0041] Any feature disclosed in this specification (including any appended claims, abstract, and drawings) may be replaced by other equivalent or similar features for a similar purpose, unless specifically stated otherwise. That is, unless specifically stated otherwise, each feature is merely one example of a series of equivalent or similar features.
[0042] Example 1
[0043] 90 mL of tetrahydrofuran and 10 g of compound A were added to a reaction flask. Under nitrogen protection, the mixture was cooled to -5°C to 0°C, and 5 g of potassium tert-butoxide was added. After the addition was complete, the mixture was kept at this temperature for 1 hour. Then, the temperature was raised to room temperature, and 12.7 g of compound B was added. The mixture was kept at this temperature and stirred for 2 hours. The resulting reaction solution was added dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid. The mixture was kept at room temperature for 2 hours. 23.4 g of ammonia water was added to the reaction system, and the mixture was heated under reflux for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, allowed to stand, and the ammonia water layer was separated. An appropriate amount of water was added, and the mixture was cooled to 0°C and stirred to induce crystallization for 2 hours. The mixture was filtered, and the filter cake was dried at 40-50°C for 6 hours to obtain the etoricoxib sample. The content of compound B in the sample was determined to be 383 ppm.
[0044] Example 2
[0045] Add 90 mL of tetrahydrofuran and 10 g of compound A to a reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and maintain the reaction temperature for 1 h. Then, heat to room temperature and add 12.7 g of compound B, and maintain the temperature and stir for 2 h. Add the resulting reaction solution dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid, and react at room temperature for 2 h. Add 23.4 g of ammonia water to the reaction system, heat to reflux for 2 h, and after the reaction is complete, cool to room temperature, let stand, and separate the ammonia water layer. Add 20 mL of 5 wt% sodium hydroxide solution, stir for 30 minutes, let stand, separate the aqueous layer, add an appropriate amount of water, cool to 0℃, stir to precipitate crystals for 2 h, filter, and dry the filter cake at 40-50℃ for 6 h to obtain the etoricoxib sample. The content of compound B was detected to be 15.1 ppm.
[0046] Example 3
[0047] Add 90 mL of tetrahydrofuran and 10 g of compound A to a reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and maintain the reaction temperature for 1 h. Then, heat to room temperature, add 12.7 g of compound B, and maintain the temperature with stirring for 2 h. Add the resulting reaction solution dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid, and react at room temperature for 2 h. Add 23.4 g of ammonia water to the reaction system, heat to reflux for 2 h, and after the reaction is complete, cool to room temperature, let stand, and separate the ammonia water layer. Add 20 mL of 5 wt% sodium hydroxide solution, stir for 30 minutes, let stand, and separate the aqueous layer. Add another 20 mL of 5 wt% sodium hydroxide solution, stir for 30 minutes, let stand, and separate the aqueous layer. Add an appropriate amount of water, cool to 0℃, stir to precipitate crystals for 2 h, filter, and dry the filter cake at 40-50℃ for 6 h to obtain the etoricoxib sample. The content of compound B was detected to be 2.9 ppm.
[0048] Example 4
[0049] Add 90 mL of tetrahydrofuran and 10 g of compound A to the reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and keep the reaction at this temperature for 1 h. Then, raise the temperature to room temperature, add 12.7 g of compound B, and keep the reaction at this temperature with stirring for 2 h. The resulting reaction solution was added dropwise to tetrahydrofuran containing 18.7 g glacial acetic acid and reacted at room temperature for 2 hours. Then, 23.4 g ammonia was added to the reaction system, and the mixture was heated under reflux for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, allowed to stand, and the ammonia layer was separated. 20 ml of 5 wt% sodium hydroxide solution was added, and the mixture was stirred for 30 minutes. The aqueous layer was separated, and another 20 ml of 5 wt% sodium hydroxide solution was added, and the mixture was stirred for 30 minutes. The aqueous layer was separated, and another 20 ml of 5 wt% sodium hydroxide solution was added, and the mixture was stirred for 30 minutes. The aqueous layer was separated, and an appropriate amount of water was added. The mixture was cooled to 0°C and stirred to induce crystallization for 2 hours. The mixture was filtered, and the filter cake was dried at 40-50°C for 6 hours to obtain the etoricoxib sample. Compound B was not detected in the sample.
[0050] Example 5
[0051] Add 90 mL of tetrahydrofuran and 10 g of compound A to a reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and maintain the reaction temperature for 1 h. Then, heat to room temperature, add 12.7 g of compound B, and maintain the temperature with stirring for 2 h. Add the resulting reaction solution dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid, and react at room temperature for 2 h. Add 23.4 g of ammonia water to the reaction system, heat to reflux for 2 h, and after the reaction is complete, cool to room temperature, let stand, and separate the ammonia water layer. Add 20 mL of 1% sodium hydroxide solution, stir for 30 minutes, let stand, separate the aqueous layer, add an appropriate amount of water, cool to 0℃, stir to precipitate crystals for 2 h, filter, and dry the filter cake at 40-50℃ for 6 h to obtain etoricoxib sample. The content of compound B in the sample was detected to be 142 ppm.
[0052] Example 6
[0053] Add 90 mL of tetrahydrofuran and 10 g of compound A to a reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and maintain the reaction temperature for 1 h. Then, heat to room temperature, add 12.7 g of compound B, and maintain the temperature and stir for 2 h. Add the resulting reaction solution dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid, and react at room temperature for 2 h. Add 23.4 g of ammonia water to the reaction system, heat to reflux for 2 h, and after the reaction is complete, cool to room temperature, let stand, separate the ammonia water layer, add 20 mL of 10% sodium hydroxide solution, stir for 30 minutes, let stand, separate the aqueous layer, add an appropriate amount of water, cool to 0℃, stir to precipitate crystals for 2 h, filter, and dry the filter cake at 40-50℃ for 6 h to obtain etoricoxib sample. The content of compound B was detected to be 12.6 ppm.
[0054] Example 7
[0055] Add 90 mL of tetrahydrofuran and 10 g of compound A to a reaction flask. Under nitrogen protection, cool to -5℃ to 0℃, add 5 g of potassium tert-butoxide, and maintain the reaction temperature for 1 h. Then, heat to room temperature, add 12.7 g of compound B, and maintain the temperature with stirring for 2 h. Add the resulting reaction solution dropwise to tetrahydrofuran containing 18.7 g of glacial acetic acid, and react at room temperature for 2 h. Add 23.4 g of ammonia water to the reaction system, heat to reflux for 2 h, and after the reaction is complete, cool to room temperature, let stand, and separate the ammonia water layer. Add 20 mL of 5 wt% sodium carbonate solution, stir for 30 minutes, let stand, separate the aqueous layer, add an appropriate amount of water, cool to 0℃, stir to precipitate crystals for 2 h, filter, and dry the filter cake at 40-50℃ for 6 h to obtain the etoricoxib sample. The content of compound B was detected to be 322.5 ppm.
[0056] like Figure 1 The figure shows a comparison of the solubility of compound B in water, 5 wt% sodium hydroxide solution, and etoricoxib in 5 wt% sodium hydroxide solution. As can be seen from the figure, compound B has good solubility in alkaline water, while etoricoxib is almost insoluble in alkaline water.
[0057] The purified etoricoxib samples obtained in Examples 1-7 above were tested sequentially using the external standard method to obtain the following results: Figure 2-8 The test spectra shown in sequence were used to calculate the content of compound B as recorded in each embodiment.
[0058] Calculation: The content of 2-chloro-1,3-bis(dimethylamino)trimethylhexafluorophosphate (compound B) was calculated using the external standard method.
[0059]
[0060] In the formula:
[0061] A SAP : Peak area of compound B in the test solution;
[0062] A STD The peak area of compound B in the test results of the reference solution;
[0063] C STD : Concentration of reference solution (0.125 μg / mL compound B);
[0064] C SAP : Concentration of the test solution (10 mg / mL etoricoxib).
[0065] To ensure drug safety, the content of 2-chloro-1,3-bis(dimethylamino)trimethylhexafluorophosphate (compound B), calculated by the external standard method, should not exceed 12.5 ppm.
[0066] As can be seen from the above embodiments, Examples 2-6, which use the alkaline water washing method of the present invention to remove impurities, have achieved excellent impurity removal effects. In particular, in Examples 2, 3, and 4, the content of compound B is no higher than 12.5 ppm, while in Example 6, the content of compound B is only 12.6 ppm, which almost meets the requirements.
[0067] This invention is not limited to the specific embodiments described above. The invention extends to any new feature or combination disclosed in this specification, as well as any new method or process step or combination disclosed herein.
Claims
1. A method for purifying impurities based on coxib, characterized in that, Includes the following steps: Step (1): Preparation of tetrahydrofuran reaction solution of etoricoxib. Specifically: Compound A and compound B undergo electrophilic addition reaction under potassium tert-butoxide conditions according to the required reaction ratio, and then are added to glacial acetic acid to complete the quenching reaction. Finally, the mixture is heated in ammonia water to generate etoricoxib by cyclization of the Schiff base active intermediate, thereby obtaining the tetrahydrofuran reaction solution of etoricoxib. Among them, compound A is 1-(6-methyl-3-pyridine)-2-[4-(methmercapto)phenyl]-ethyl ketone, and compound B is 2-chloro-1,3-bis(dimethylamino)trimethylene hexafluorophosphate. Step (2): Wash the tetrahydrofuran reaction solution of etoricoxib obtained in step (1) with an inorganic alkali solution 1-3 times. The inorganic alkali content in the inorganic alkali solution is 1wt%-10wt%. Each time, add the inorganic alkali solution to the tetrahydrofuran reaction solution of etoricoxib at a ratio of 10 g : (10-50) mL, stir, let stand and separate the layers. After separating the water layer, the first alkali wash is completed. After the last alkali wash, cool down to crystallize and finally obtain the purified etoricoxib product.
2. The method for purifying etoposide impurities according to claim 1, characterized in that, In step (2), during alkaline washing, an inorganic alkaline solution is added to the tetrahydrofuran reaction solution of etoricoxib at a ratio of 10 g: 20 mL between the mass of compound A and the volume of the inorganic alkaline solution.
3. The method for purifying etoricoxib impurities according to claim 1, characterized in that, In step (2), the inorganic bases in the inorganic base solution include sodium hydroxide, potassium hydroxide, and sodium carbonate.
4. The method for purifying etoricoxib impurities according to claim 3, characterized in that, In step (2), the inorganic base in the inorganic base solution is sodium hydroxide.
5. The method for purifying etoricoxib impurities according to claim 1, characterized in that, In step (2), the inorganic alkali content in the inorganic alkali solution is 5 wt%.
6. The method for purifying etoricoxib impurities according to claim 1, characterized in that, In step (2), the alkaline washing is performed twice.
Citation Information
Patent Citations
Method for preparing etocoxib
CN104151232A
Synthesis method of etoricoxib
CN104693113A
Process for synthesizing Cox-2 inhibitors
CN1178658C
Process for synthesizing Cox-2 inhibitors
CN1306425A
